SNAP Biosciences

Ushering In the **Next Generation** of CAR-Based Therapeutics

Company Overview
2025

Disclosures and Disclaimers

This document has been prepared to provide a guide to the Company implementing its growth strategies and the details have been checked and approved by the Directors of the Business. The Directors of the Business make no representation or warranty as to the accuracy or completeness of this document. This document is intended to serve as a business overview for potential investments; however SNAP Biosciences reserves the right to make such changes and amendments that it sees fit in its sole discretion with respect to any specific potential investment. This document has been provided for informational purposes only and does not constitute legal advise. There are considerable risks involved with potential investment with the Company, including, without limitation, the risks identified herein. Any potential investment is suitable only for persons who have no need for liquidity in their investment and who can bear the risk of potential loss of their entire investment.

Potential acquirers, investors, or lenders must conduct their own reviews and satisfy themselves in terms of the Business and its prospects for the future. The Directors accept no liability for any loss or damage whatsoever which may occur as a result of reliance on the information in this document.

Company Overview

At SNAP Biosciences, we are developing a “universal” CAR platform called SNAP-CAR that is designed to overcome several limitations of current CAR-based therapeutics. With our SNAP-CAR NK cells we aim to **usher in the next generation of cell therapy.**

SNAP-CAR Technology



SNAP-CAR is a highly modular CAR-based platform that, instead of binding directly to target antigens, binds to targeting antibodies that direct SNAP-CAR effector cells to target cells.

+

Allogeneic NK Cells



We utilize a proprietary pooled-donor umbilical cord stem cell platform that enables the production of safe, and effective, truly “off-the-shelf” NK cell therapies.

=

Revolutionary Clinical Potential

By combining SNAP-CAR with our truly off-the-shelf NK cells, we can easily and efficiently treat a wide array of diseases including solid and liquid cancers, as well as autoimmune disorders.

The Future of Cell Therapy Is Bright

Cell therapies have been proven to **offer curative potential for cancers** and other diseases, often outperforming traditional therapies.

2 key indicators of a strong future for cell therapy

Strong market growth

The global cell therapy market is projected to grow at a **CAGR of 23%, reaching over $37 billion by 2033**, with CAR-based and NK-based therapies playing a prominent role[1].

Rapidly Expanding Indications

Traditionally successful in treating hematologic malignancies, cell therapies are now advancing into **solid tumors and autoimmune diseases.**

Prominent Therapeutic: CAR-Based Cell Therapies



CAR-Based therapeutics have a simple mechanism of action:

1. Design CAR to recognize a molecule on the surface of cancer cells.
2. Express CAR in highly cytotoxic immune cell like a T cell or an NK cell
3. CAR directs immune cell to find and kill cancer cells

There are currently 7 FDA approved CAR-T cell products targeting either CD19 (5/7) or BCMA (2/7) for the treatment of B cell malignancies.

Key Limitations that Restrict CAR-T Market

Despite their popularity and success, CAR-based therapies suffer from several limitations that restrict their clinical use and therapeutic impact.

1

Rigid Antigen Targeting

Traditional CARs “hard-code” antigen specificity into the receptor, **requiring entirely new designs** to target different antigens.

2

Toxicities

CAR-T cell-based therapies are associated with **severe toxicities** including cytokine release syndrome and neurotoxicity.

3

Time & Costs

Treatments are highly personalized taking up to 6 weeks to receive infusions and costing upwards of **$350,000–$500,000 per patient**.

Key Limitations that Restrict CAR-T Market

Despite their popularity and success, CAR-based therapies suffer from several limitations that restrict their clinical use and therapeutic impact.

Our SNAP-CAR NK Cell platform is designed to **combat each of these limitations**

NK Cells Offer Distinct Advantages Over T Cells



Cytotoxic innate cells with powerful anti-cancer capabilities

- Recognize cancer cells through a **variety of mechanisms**.
- Release cytotoxic substances and kill target cells efficiently.
- Trigger a broader anti-cancer response, **activating nearby immune cells**.

More convenient “off-the-shelf” cell option

- Do not attack healthy cells unlike T cells – **safe**.
- Can therefore be used without any genetic modification – **quick and cost-effective**.

3 Key Components of SNAP-CAR Technology

1

Universal, Truly "Off-The-Shelf" **NK Cells**

EFFECTIVE STANDALONE THERAPY

Pooled UCB Stem Cell-Derived:
Do not require HLA matching!



2

SNAP-CAR **Receptor**



3

BG-Tagged FDA-Approved **mAbs**



Mechanism of Action

SNAP-CAR-NK Cells are administered in combination with BG-tagged mAbs. The two components cooperate to eliminate target cells.



Our SNAP-CAR NK Platform Overcomes Prominent Limitations

Our universal SNAP-CAR NK cell therapy is designed to overcome several of the key challenges facing CAR-based therapy field.

1

More Control Over Toxicities

By combining the intrinsic safety of NK cells with the tunable activity of SNAP-CAR, **our therapy is much safer than traditional CAR-T therapies**.

2

Dynamic Antigen Targeting

SNAP-CAR enables flexible targeting by using interchangeable antibodies, **addressing antigen escape and combatting antigen-negative recurrence**.

3

Quick & Cost-Effective

Combining the off-the-shelf nature of our cells with the dynamic nature by which we can change the target antigen of SNAP-CAR, our platform is **very cost-effective and highly scalable**.

SNAP-CAR NK Gives More Control Over Toxicities

1

Modular Design of SNAP-CAR gives us more control over toxicities

- Since the SNAP-CAR NK cells are reliant on the presence of the targeting antibody for activity, we can **easily tune their activity** by modulating the level of antibody.



2

NK Cells are a safer donor-derived cell type than T cells

- Unlike T cells, NK cells are inhibited by MHC on healthy, normal cells. So, donor cells will not induce GvHD upon infusion.
- Also, NK cells do not expand as robustly or release the high levels of cytokines associated with T cells, making them much safer for cell therapy.



SNAP-CAR Provides 2 Mechanisms to Overcome Antigen Escape

①

Multi-antigen targeting can be achieved by simply administering multiple BG-tagged mAbs, providing a simple way to overcome antigen escape.



②

By administering higher concentrations of BG-tagged antibody, we can easily lower antigen threshold to eliminate antigen-low cells.



“Unlimited” Therapeutic Potential of SNAP-CAR Cell Therapy

One population *of SNAP-CAR-NK cells*



Universal NK cells:
Do not require HLA matching!

+

Library *of BG-tagged mAbs*



Vast array *of patients*



“Unlimited” Therapeutic Potential of SNAP-CAR Cell Therapy

SNAP-CAR NK cells can be used to treat **both solid and liquid cancers**, as well as **autoimmunity**.



CD19-Positive B Cell

HER2-Positive BC Cell

Autoreactive B Cell

The Future of Multi-Specific CAR-NK Cell Therapy Is Bright

Global NK Market is growing rapidly

- Global NK market is projected to grow at an outstanding **44.3% CAGR from 2022-2031 to an expected value of $3.16B⁺**.



NK cell therapy

⁺according to Straits research - 2024

Multi-Specific CAR platforms are gaining prominence

- Growing number of CAR trials now involve **multispecific or modular CAR platforms**, like SNAP-CAR



CAR-Effector

SNAP-CAR NK is a Highly Differentiated Approach

SNAP-CAR NK is Differentiated in this space

- Coeptis is the only universal CAR platform that has optimized its technology for use in **donor-derived NK cells.**
- SNAP-CAR receptor forms a **strong, covalent bond with the targeting antibody**, ensuring efficient transduction of signaling upon ligand binding.

Universal CAR-T Platforms		
Developer	**Platform**	**Cell Type and Source**
SNAP Biosciences	**SNAP-CAR**	**Donor-Derived NK**
ARCELLX	ARC-T	Autologous T
AVENCELL	UniCAR	Donor-Derived T
BIAT group.com biotechnology assets	Click CAR	Unspecified
BIOSCEPTRE	BRiDGECAR	Autologous T
Calibr at Scripps Research	sCAR-T	Autologous T
Umoja BIOPHARMA	TumorTag	*In Vivo* Delivery to T

Potential Clinical Opportunity: B Cell Malignancies

B Cell Malignancies

Target antigens:
CD19, CD20, CD22, CD72

Over 80,000 Americans are diagnosed with B-cell malignancies annually*, primarily including B cell Non-Hodgkin's Lymphoma, and B-ALL

All approved CAR-T products for B cell malignancies target CD19

Multi-Antigen Approach

Targeting Strategy:
CD19 + CD20 + CD22 + CD72

Many patients relapse with antigen-negative disease. By co-administering multiple targeting antibodies, we can provide deeper, longer remissions.



*According to statistics provided by the American Cancer Society – 2024.

Potential Clinical Opportunity: Solid Tumors

Solid Tumors

Target antigens:
HER2, EGFR, CLDN6

Antibody therapeutics are commonly used to target multiple solid tumor indications, and several CAR-based approaches are being tested.

**no approved CAR-T products in the US for solid tumors*



- This is the ultimate goal, unlocking the full potential of SNAP-CAR NK cells.
- Massive transformative impact across oncology and beyond.

Thank You!

...

Company Overview
2025